On the contrary, 4F2hc immunoreactivity was markedly stronger than LAT1 immunoreactivity in tumor cells, and these results suggest there are different expression regulation mechanisms for LAT1 and 4F2hc [1,2,5]. This evidence concerns the gene SLC3A2 and neoplasm.